DOCA-Salt Model
DOCA-salt animal is the model that represent the form of endocrine hypertension in humans with primary aldosteronism. Administration of DOCA combined with sodium chloride in unilateral nephrectomised rats cause an imbalance of renal sodium handling, resulting in hypertension. In addition, DOCA-salt rats/mice have increased arterial wall thickness, renal function damage and so on. Though the exact mechanism of hypertension in DOCA-salt rats remain unclear, increasing evidence indicates that the occurence of DOCA-salt hypertension associates with the overactive sympathetic nervous system and an imbalance in the reninangiotensin system (RAS). Thus, this model is ideal for studying the role of the above single pathways on hypertension pathogenesis.
Creative Bioarray focuses on drug research and development services and helps customers test the efficacy of novel drugs against hypertension and understand the pathological mechanisms by DOCA-Salt model.
Species available
- Rat
- Mouse
Our capabilities
- We screen novel test compounds targeting hypertension.
- Blood pressure (BP) was monitored by tail-cuff.
Assays available
- PK/PD collection
- Pathological evaluation
- Cytokine analysis
- ECG
- Blood pressure monitoring
With extensive experience in the field of hypertension, we are confident to help you to overcome any upcoming challenges. Our experts are fully capable of customizing our protocols and assays to meet your specific needs. With our help, we wish to facilitate your research with high efficiency.
Study examples
Figure. 1. MCC950 reduces BP in mice with 1K/DOCA/salt-induced hypertension. Effects of 1K/DOCA/salt and MCC950 on systolic BP (A), diastolic BP (B), mean arterial pressure (C), and heart rate (D) measured by radiotelemetry at 10 min-intervals and plotted as an average over a 3-day period.
Quotation and ordering
If you have any special needs or questions regarding our services, please feel free to contact us. We look forward to cooperating with you in the future.
Reference
Krishnan S M, Ling Y H, Huuskes B M, et al. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension[J]. Cardiovascular research, 2018, 115(4): 776-787.
